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Sustained improvements in Glucose 
Metabolism Late After Roux-en-Y 
Gastric Bypass Surgery in patients 
with and Without preoperative 
Diabetes
nils B. Jørgensen1,3*, Kirstine N. Bojsen-Møller1, Carsten Dirksen1, Christoffer Martinussen1, 
Maria S. Svane1,3, Viggo B. Kristiansen2, Jens J. Holst3,4 & Sten Madsbad1,4
To describe glucose metabolism in the late, weight stable phase after Roux-en-Y Gastric Bypass (RYGB) 
in patients with and without preoperative type 2 diabetes we invited 55 RYGB-operated persons from 
two existing cohorts to participate in a late follow-up study. 44 (24 with normal glucose tolerance 
(NGT)/20 with type 2 diabetes (T2D) before surgery) accepted the invitation (median follow-up 2.7 
[Range 2.2–5.0 years]). Subjects were examined during an oral glucose stimulus and results compared 
to preoperative and 1-year (1 y) post RYGB results. Glucose tolerance, insulin resistance, beta-cell 
function and incretin hormone secretion were evaluated. 1 y weight loss was maintained late after 
surgery. Glycemic control, insulin resistance, beta-cell function and GLP-1 remained improved late 
after surgery in both groups. In NGT subjects, nadir glucose decreased 1 y after RYGB, but did not 
change further. In T2D patients, relative change in weight from 1 y to late after RYGB correlated with 
relative change in fasting glucose and HbA1c, whereas relative changes in glucose-stimulated insulin 
release correlated inversely with relative changes in postprandial glucose excursions. In NGT subjects, 
relative changes in postprandial nadir glucose correlated with changes in beta-cell glucose sensitivity. 
Thus, effects of RYGB on weight and glucose metabolism are maintained late after surgery in patients 
with and without preoperative T2D. Weight loss and improved beta-cell function both contribute to 
maintenance of long-term glycemic control in patients with type 2 diabetes, and increased glucose 
stimulated insulin secretion may contribute to postprandial hypoglycemia in nGt subjects.
Roux-en-Y gastric bypass surgery (RYGB) is a highly effective obesity treatment, resulting in 30–40% weight 
loss after 1 year1. Additionally, it is the most efficient treatment of type 2 diabetes (T2D) in morbidly obese indi-
viduals, improving glucose tolerance profoundly within days in the majority of patients and providing superior 
glycemic control up to 5 years after surgery compared with intensive medical treatment alone2,3.
The mechanisms responsible for improving T2D glucose metabolism are still being debated, but early after 
surgery, the combined effects of caloric restriction and an exaggerated postprandial GLP-1 release, improv-
ing hepatic insulin sensitivity and beta-cell function, respectively, are among the most likely explanations4. 
Continued postprandial hypersecretion of anorexigenic gut-hormones limiting appetite and food intake, and 
leading to weight loss and increased peripheral insulin sensitivity, may explain later effects of RYGB on glucose 
metabolism5–9.
However, epidemiological reports have questioned the durability of surgery in some patients, and indicated 
that weight regain and deteriorating glycemic control may occur late after surgery10,11. Thus, 25–50% of patients 
with diabetes remission at 1 year will have relapsed 5 years after RYGB12,13, but determining physiological factors 
of glycemic control late after surgery is not well characterized.
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In persons with normal glucose tolerance (NGT) before the operation, a late complication to RYGB is post-
prandial hypoglycemia14. This has been linked to exaggerated insulin release in response to rapid increases in 
postprandial glucose and GLP-1 concentrations15,16.
To address the development of these glycemic disturbances, we studied the effects of RYGB on glycemic con-
trol as well as measures of insulin sensitivity, beta-cell function and body weight late after RYGB surgery in 
patients with NGT or T2D prior to surgery, and results were compared to preoperative and 1-year (1 y) post 
RYGB results. Additionally, we describe how changes in these physiological parameters relate to changes in glyce-
mic control in patients with T2D and with postprandial glucose nadir in subjects with NGT.
Materials and Methods
Subjects. Patients with NGT or T2D, who had participated in one of 3 previous studies (ClinicalTrials.gov ID: 
NCT00810823, NCT01993511, NCT01202526) evaluating the earlier effects of RYGB in response to an oral glu-
cose stimulus, were invited to participate in a late follow-up, performed >2 years after surgery. Cohort 1: Subjects 
from two previous studies who received RYGB surgery >2 years prior to May 20136,17; Cohort 2: subjects from a 
previous study studied 3.5–5 years after RYGB9. Preoperative glucose tolerance is defined in Table 1. Antidiabetic 
medications were discontinued 3 days (GLP-1 receptor agonists: ≥10 days) before each study day; all antidiabetic 
medications were discontinued from time of surgery. Before inclusion, all participants fulfilled the inclusion 
criteria for bariatric surgery in Denmark and had completed a preoperative diet-induced total body weight loss 
of at least 8% required by the Danish health authorities. All trial extensions were approved by the Danish Capital 
Region Municipal Ethical Committee and by the Danish Data Protection Agency and the study performed in 
accordance with the Helsinki-II declaration.
Surgical procedure. Standard RYGB procedure as previously described6.
oral stimulation tests. Three fasting blood samples were drawn after an overnight fast (10 h), followed 
by a liquid mixed meal test in Cohort 1 (200 ml Fresubin Energy Drink [300 kcal, carbohydrate (E% 50), protein 
(E% 15), fat (E% 35), Fresenius Kabi, Deutschland, Bad Homburg, Germany]) or an oral glucose tolerance test 
(OGTT) in Cohort 2 (75 g anhydrous glucose dissolved in 250 ml of water). Following the oral stimulus (T = 0), 
blood was sampled frequently for 180 min in cohort 1 and for 120 min in cohort 2 (15, 30, 45, 60, 90, 120 min, and 
in Cohort 1 only, 180 min).
Sample collection. Blood samples were collected in clot-activator tubes for C-peptide and insulin analyses, 
left to coagulate for 30 min, spun, aliquoted, frozen and stored at −80 C. Blood for glucose analysis was collected 
in prechilled EDTA-tubes, blood for GIP and GLP-1 measurements was collected in prechilled EDTA tubes con-
taining a DPP-4 inhibitor (valine-pyrrolidide; 0.01 mmol/l, final concentration), immediately cooled on ice and 
centrifuged at 4 °C. Plasma for GIP and GLP-1 analysis were stored at −20 C.
Laboratory analyses. Glucose was measured bedside using the glucose oxidase technique (YSI model 2300 
STAT Plus, Yellow Spring Instruments, Yellow Spring, OH). Serum insulin and C-peptide concentrations were 
determined using AutoDELFIA fluoroimmunoassay, Wallac OY, Turku, Finland6, or the Immulite 2000 analyzer, 
Siemens Healthcare Diagnostics, Tarrytown, NY9,17) analyzed in one batch per cohort. Similarly, incretins were 
measured in one batch (e.g. including re-analysis of preoperative and 1-year samples) in Cohort 1 only, due to 
lack of plasma to reanalyze in cohort 2. For the same reasons, incretins were only analyzed in the fasting state and 
at one timepoint postprandially (T = 45 min for GLP-1 and T = 60 min for GIP). Total GLP-1 and GIP was ana-
lyzed as previously described18, using a radioimmunoassay (RIA, antiserum no. 89390) specific for the C-terminal 
of the GLP-1 molecule and reacting equally with intact GLP-1 and the primary (N-terminally truncated) metabo-
lite; Total GIP was assayed using the C-terminally directed antiserum #867, which equally recognizes both intact 
GIP (1–42) and the primary metabolite, GIP (3–42)19.
calculations and statistical analyses. Data are expressed as means ± SE. Total area-under-the-curve 
(T-AUC) was calculated using the trapezoidal model. Excess body weight loss (EBWL) was calculated as (pre-
operative BMI − study BMI)/(preoperative BMI − 25) × 100%. HOMA2-IR C-peptide was calculated using the 
University of Oxford HOMA calculator (www.dtu.ox.ac.uk/homacalculator/download.php). Prehepatic insulin 
secretion rates (ISR) were calculated by deconvolution of peripheral C-peptide concentrations and application of 
population-based parameters for C-peptide kinetics using the ISEC software20,21 and expressed as pmol·kg−1·min−1. 
Beta-cell glucose sensitivity (bGS), i.e. increment in ISR in response to 1 mmol/L increase in plasma glucose, 
NGT
Fasting plasma glucose <6.1 mM
and
2 hour OGTT plasma glucose <7.8 mM
and
HbA1c <42 mmol/mol
T2D
Fasting plasma glucose >7.0 mM
and/or
2 hour OGTT plasma glucose >11.1 mM
and/or
Treatment with ≥1 antidiabetic agents
Table 1. Definition of preoperative glycemic control.
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was calculated as previously described during the upslope of the glucose curve (meal start to peak glucose)6. 
Disposition index (DI) was calculated as bGS × insulin sensitivity (1/HOMA2-IR). Relative changes from 1 y 
to late after RYGB, were calculated as (relevant valuelate/relevant value1y − 1)∙100%. Relative changes in weight, 
insulin resistance and beta-cell function, were related to the relative change in measures of glycemic control and 
nadir glucose using a linear regression model in the individual groups (NGT/T2D). The correlation coefficient 
was calculated using Pearsons correlation analysis for each group.
Weight loss failure was defined as EBWL less than 50%22. Diabetes remission was defined according to ADA 
criteria23.
Within group postoperative changes were analyzed with Wilcoxon’s matched pairs signed rank test, between 
group differences with Wilcoxon’s signed rank test. Comparison of proportions between groups were done using 
the Chi-squared test. A p-value < 0.05 was considered statistically significant. Calculations and statistical analyses 
were performed with the R statistical software (R version 3.3.2)24.
ethical statement. All procedures performed in studies involving human participants were in accordance 
with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards.
consent statement. Informed consent was obtained from all individual participants included in the study.
Results
Of 55 eligible subjects, 44 accepted the invitation to the late follow-up (24 NGT, age: 44 ± 2 years/20 T2D, age: 
49 ± 2 years, median follow-up 2.7 [Range 2.2–5.0 years] (Fig. 1). Patients lost to follow-up did not differ from 
participants with respect to preoperative age, bmi, hba1c or diabetes duration or with respect to 1 y postopera-
tive EBWL (data not shown). 3 patients (2 T2D/1 NGT) in cohort 2 refused the OGTT postoperatively due to a 
general distaste for the oral stimulus, previous problems with malfunctioning iv access and/or lack of time. These 
patients are represented with biometric and fasting data only. Preoperative antiglycemic treatment is shown in 
Table 2. All but two T2D patients, were without antidiabetic medication at the late follow-up. Patient character-
istics are presented in Table 3.
Weight loss and biometric data. Patients lost weight during the first year after surgery, but late after 
RYGB, weight was unchanged from that at 1 y (Table 3). While average BMI was still >30, both groups had a 
mean excess body weight loss (EBWL) of more than 60%. The proportion of participants with EBWL <50% at 1 y 
was 35% and 34% late after surgery. EBWL late after surgery was numerically lower in the T2D patients, but the 
Figure 1. (A) Flow chart illustrating the inclusion of patients. (B) Flow of included patients in the study.
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proportion of patients with >50% EBWL was the same irrespective of diabetes status (NGT: 17/24; T2D: 12/20, 
p = 0.45). Weight change from 1 y to late follow-up did not differ between cohort 1 and 2 (p = 0.11). As subjects 
lost weight, waist/hip ratio declined.
Diet MET MET + SU MET + LIRA MET + SU + EX MET + SU + TZD MET + INS
Number 2 10 4 1 1 1 1
Table 2. Preoperative antiglycemic treatment in patients with type 2 diabetes. MET = Metformin, 
SU = Sulfonylurea, LIRA = Liraglutide, EX = Exenatide, TZD = Glitazone, INS = Insulin.
NGT T2D
Pre 1 y Late Pre 1 y Late
Number 24 20 24 20 19 20
Male gender 6 6 6 12 12 12
Time after surgery (weeks) −0.5 [−1.8–0.4] ± 0.8 53 [52–55]- 143 [131–200] ± 11 −0.5 [−2.4–0.1] 54 [53–57] 139 [132–223]
BMI (kg/m2) 41.6 ± 0.9 31.4 ± 1.2** 31.0 ± 1.1** 40.7 ± 1.1 31.6 ± 1.3** 32.1 ± 1.4**
EBWL (%) 0 ± 0 67 ± 6** 68 ± 6** 0 ± 0 65 ± 6** 61 ± 8**
Waist (cm) 123 ± 2 99 ± 3** 96 ± 3** 128 ± 3 107 ± 3** 106 ± 4**
Hip (cm) 127 ± 2 105 ± 2** 107 ± 2** 120 ± 2‡ 105 ± 2** 107 ± 2**
Waist-hip ratio 0.98 ± 0.02 0.94 ± 0.02* 0.89 ± 0.02** 1.07 ± 0.03 1.02 ± 0.03* 0.99 ± 0.03*
Table 3. Weight and biometrics. *p < 0.05 vs pre; **p < 0.001 vs pre; †p < 0.05 vs 1 y; ‡p < 0.05 vs NGT at 
corresponding time point. All parameters are mean ± SEM, except time after surgery, which is Median [IQR].
NGT T2D
Pre 1 y Late Pre 1 y Late
Glycemic control
HbA1c (mmol/mol) 36 ± 0.7 35 ± 0.7* 36 ± 0.9 52 ± 2‡‡ 38 ± 1**,‡ 42 ± 2**,†,‡
Fasting Glucose (mmol/L) 5.3 ± 0.1 4.9 ± 0.1** 4.9 ± 0.1** 8.8 ± 0.4‡‡ 5.8 ± 0.3**, ‡‡ 6.0 ± 0.3**, ‡
Peak Glucose (mmol/L) 7.6 ± 0.3 9.2 ± 0.3** 9.5 ± 0.4** 14.3 ± 0.8‡‡ 11.9 ± 0.6*,‡‡ 12.7 ± 0.7‡‡
Postprandial nadir glucose (mmol/L) 5.3 ± 0.2 3.9 ± 0.2** 3.8 ± 0.2** 9.2 ± 0.5‡‡ 5.5 ± 0.3**,‡‡ 6.2 ± 0.5**,‡‡
IAUC Glucose (mol × min/L) ‡‡ *, ‡‡ ‡‡
Cohort 1 (0–180 min) 80 ± 21 81 ± 18 94 ± 40 367 ± 40 239 ± 26 301 ± 49
Cohort 2 (0–120 min) 244 ± 36 271 ± 58 331 ± 65 665 ± 74 564 ± 66 667 ± 63
Insulin secretion
Fasting Insulin (pmol/L) 88 ± 8 34 ± 4** 36 ± 4** 139 ± 16‡ 46 ± 7** 54 ± 7**
Peak Insulin (pmol/L) 671 ± 88 889 ± 94 868 ± 109 507 ± 62 625 ± 89*,‡ 627 ± 94
IAUC Insulin (nmol × min/L)
Cohort 1 (0–180 min) 32 ± 3 38 ± 5 32 ± 5 32 ± 5 29 ± 4 25 ± 4
Cohort 2 (0–120 min) 60 ± 19 56 ± 20 67 ± 22 28 ± 7 36 ± 11 45 ± 13
Fasting C-peptide (pmol/L) 1054 ± 56 597 ± 43** 588 ± 37** 1415 ± 111‡ 746 ± 84** 822 ± 88**,‡
Peak C-peptide (pmol/L) 3620 ± 241 4434 ± 340* 4270 ± 364 3180 ± 263 3365 ± 339 3490 ± 364
IAUC C-peptide (nmol × min/L) * ‡ ** **
Cohort 1 (0–180 min) 178 ± 14 223 ± 23 211 ± 23 157 ± 18 183 ± 19 180 ± 20
Cohort 2 (0–120 min) 286 ± 47 316 ± 71 341 ± 63 159 ± 30 264 ± 43 288 ± 48
Basal ISR (pmol × min−1 × kg−1) 2.6 ± 0.13 1.8 ± 0.11** 1.7 ± 0.10** 3.3 ± 0.22‡ 2.1 ± 0.20** 2.2 ± 0.21**, ‡
IAUC ISR (pmol × kg−1) * * ‡ ** **
Cohort 1 (0–180 min) 510 ± 49 762 ± 103 676 ± 89 427 ± 46 582 ± 69 603 ± 78
Cohort 2 (0–120 min) 974 ± 149 1238 ± 279 1262 ± 247 528 ± 95 980 ± 140 1008 ± 202
Incretins (Cohort 1)
Basal GLP-1 (pmol/L) 12 ± 1 9 ± 1 12 ± 1† 12 ± 1 10 ± 1 15 ± 2†
Postprandial GLP-1 (pmol/L), T = 45 min 15 ± 1 N/A 64 ± 10** 16 ± 2 N/A 72 ± 9**
Basal GIP (pmol/L) 7 ± 1 7 ± 1 8 ± 1 10 ± 2 9 ± 1 10 ± 1
Postprandial GIP (pmol/L), T = 60 min 68 ± 9 37 ± 3* 45 ± 5** 65 ± 4 46 ± 2* 52 ± 4*
Table 4. Glycemic control, insulin and incretin secretion. *p < 0.05 vs pre, **p < 0.001 vs pre; †p < 0.05 vs 1 y, 
††p < 0.001 vs 1 y; ‡p < 0.05 vs NGT, ‡‡p < 0.001 vs NGT at corresponding time point.
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Glucose metabolism. In T2D patients, HbA1c was decreased late after surgery compared to before but had 
increased slightly compared to 1 y (Table 4). In both groups, fasting glucose concentrations remained unchanged 
late after surgery compared to 1 y, but incremental AUC glucose was only lower than preoperative values in T2D 
patients at 1y (Table 4 and Fig. 2). In T2D patients peak and nadir glucose values decreased after RYGB, whereas 
postprandial glucose excursions increased in NGT subjects after surgery with greater peak and lower nadir values 
(Table 4 and Fig. 2).
Insulin resistance, insulin secretion and beta-cell function. After surgery, insulin resistance 
(HOMA2-IR C-peptide) decreased in parallel in NGT and T2D subject and remained ~50% reduced at the late 
follow-up, but T2D patients were more insulin resistant than NGT subjects at all times (Fig. 3A). Basal prehe-
patic insulin secretion rate (basal ISR) decreased after RYGB in both groups whereas postprandial (IAUC) ISR 
increased (Table 4). The response was greater in the NGT than in the T2D group. In contrast, IAUC insulin did 
not significantly change in any of the groups. Late after surgery, bGS remained increased in T2D patients and 
Figure 2. Glucose (A + B), Insulin (C + D) and C-peptide (E + F) concentrations in Cohort 1 (MMTT, 
A + C + E) and Cohort 2 (OGTT, B + D + F). Dotted lines are T2D, solid lines NGT. Data are mean ± SE.
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unchanged in NGT subjects compared to before surgery (Fig. 3B). DI was 4-fold increased in T2D patients and 
90% increased in NGT subjects late after compared to before RYGB (Fig. 3C), despite a slight reduction in DI late 
after compared to 1 y after surgery in patients with T2D.
Incretins (cohort 1). Basal GLP-1 and GIP concentrations remained unchanged late after RYGB surgery. 
Postprandial GIP concentrations (at 60 min) were decreased and postprandial GLP-1 secretion (at 45 min) mark-
edly increased late after RYGB compared to presurgical levels (Table 4).
Diabetes status late after RYGB. Six (Cohort 1: 4/Cohort 2: 2) of 20 T2D patients had HbA1c >48 mmol/
mol (>6.5%) and/or fasting glucose >7 mmol/L late after RYGB, resulting in a 30% relapse rate late after RYGB. 
Figure 3. Effect of RYGB surgery on measures of glucose metabolism in T2D and NGT subjects. (A,B) Data 
are mean ± standard deviation, individual data points are indicated. Arrows indicate minimum and maximum 
data points. (C) Data are mean ± SEM. *p < 0.05 vs pre, **p < 0.001 vs pre; †p < 0.05 vs 1 y, ††p < 0.001 vs 1 y; 
‡p < 0.05 vs NGT, ‡‡p < 0.001 vs NGT at corresponding time point.
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Patients with diabetes relapse did not differ from patients in remission with respect to age, EBWL or insulin 
resistance, but had poorer bGS (0.9 ± 0.2 vs 1.9 ± 0.2 pmol·kg−1·min−1, p = 0.004) and DI (0.42 ± 0.04 vs. 1.2 ± 0.2 
pmol·kg−1·min−1, p = 0.010) at the late follow-up. Preoperatively, patients with diabetes relapse late after RYGB 
did not differ with respect to BMI or insulin resistance but had longer diabetes duration (8.3 ± 1.1 vs 2.9 ± 0.7 
years, p = 0.004) and poorer beta-cell glucose sensitivity (0.6 ± 0.1 vs 1.1 ± 0.1 pmol·kg−1·min−1, p = 0.026) com-
pared to late remitters.
Figure 4. Correlation of relative changes in weight, insulin resistance (HOMA), beta-cell glucose sensitivity 
(bGS) and disposition index (DI) and changes in fasting and postprandial glucose and HbA1c in patients with 
type 2 diabetes from 1 y to late after surgery.
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correlation of measures of glucose metabolism to measures of glycemic control and glucose 
tolerance. In T2D patients, the percentage (relative) weight change from 1 y to late after surgery were posi-
tively correlated with relative changes in fasting glucose concentrations and HbA1c, but not postprandial glucose 
excursions (Fig. 4). Relative changes in bGS and DI correlated inversely to changes in IAUC glucose.
In NGT subjects, relative changes in fasting glucose correlated with percent weight change (R = 0.71, 
p < 0.001). Small changes in HbA1c or postprandial glucose excursions were not associated with changes in body 
weight, insulin resistance or beta-cell function. Relative changes in postprandial nadir glucose in NGT subjects 
from 1 y to late post RYGB correlated negatively with bGS (R = −0.46, p = 0.041) but not with relative changes in 
peak C-peptide concentrations (R = −0.20, p = 0.40).
Discussion
In this follow-up study, patients with T2D or NGT prior to surgery maintained a substantial weight loss with a 
lower waist-hip ratio 2.5–4 years after RYGB. Fasting glucose and HbA1c remained significantly reduced late 
after surgery in T2D patients compared to before the operation and, although postprandial glucose excursions 
(IAUC) did not differ at late follow-up, postprandial glucose concentrations were lower. In NGT subjects, glucose 
tolerance was unchanged and nadir glucose lower late after RYGB. In both groups, insulin resistance, remained 
reduced, and DI, a measure of beta-cell function, elevated late after surgery, while GLP-1 secretion remained 
increased compared to preoperative concentrations.
The weight loss reported here corresponds well with previous studies1, while the proportion of weight loss 
failures, ie EBWL <50%, accounting for 34% of the total population, was a little higher than expected22,25. This did 
not differ between patients with T2D or NGT and had not increased compared to 1 year after surgery.
Patients with preoperative T2D as a group experienced lasting beneficial effects on basic parameters of glucose 
metabolism after RYGB: insulin resistance remained diminished and beta-cell function improved late after sur-
gery. These metabolic improvements undoubtedly explain the long-term superiority of RYGB surgery compared 
to intensive medical treatment alone2,26,27.
We and others have previously shown how the improved beta-cell function after RYGB is highly reliant on 
the exaggerated postprandial GLP-1 secretion28–30, and indeed we found that postprandial GLP-1 concentra-
tions were elevated late after RYGB as previously reported earlier after surgery, indicating that the capacity of 
the gut to hypersecrete GLP-1 and the stimulatory effect of GLP-1 on beta-cells does not wane9,17,31. However, 
this prolonged GLP-1 stimulation in RYGB patients does not lead to a further improvement in beta-cell function 
either. GIP secretion appeared attenuated late after RYGB surgery, but this finding must be interpreted cautiously 
because of the limited postprandial samples.
T2D patients may experience weight regain and deteriorating glucose tolerance late after surgery10,11. In this 
study, patients who had diabetes relapse were characterized by longer preoperative diabetes duration, which is 
in accordance with previous findings32, and poorer beta-cell function both before and after surgery compared 
with patients who remained in remission late after RYGB. This stresses the importance of beta-cell function in 
T2D glucose metabolism33. It is important to recognize that patients in this study still had diabetes immediately 
pre-surgery after completion of a required pre-operative 8% weight loss, which substantially improves glucose 
metabolism34. Thus, by design, our study, selected patients with more severe diabetes, and in this context a remis-
sion rate of 70% is impressive.
Our correlation analyses show that maintenance of weight loss and postoperative improvements in beta-cell 
function are important for persisting improvements in post RYGB glycemic control in patients with preoperative 
T2D. Since postprandial GLP-1 hypersecretion after RYGB causes both improved beta-cell function, and sup-
presses appetite and decreases food intake together with other hypersecreted anorexigenic gut hormone, these 
findings support that GLP-1 plays a central role for the beneficial effects of this surgery8,35–37.
In patients with preoperative NGT, we demonstrated an association between changes in fasting glucose and 
weight loss after surgery, which is to be expected, and a negative correlation between nadir glucose and bGS. The 
latter association is mechanistically sound, and could reflect insulinotropic effects of the exaggerated postprandial 
GLP-1 release16,28,38. However, an association could not be shown between changes in peak C-peptide concentra-
tions, another measure of beta-cell secretory capacity, and nadir glucose concentrations, possibly reflecting the 
importance of early insulin secretion for glucose tolerance39.
Only 80% of eligible subjects participated in the late follow-up session, introducing the risk of selection bias, 
but dropouts did not differ from participants with respect to basic preoperative and 1 y postoperative character-
istics. Another limitation is the use of two different oral stimuli, but since participants were their own controls 
and we defined diabetes relapse from fasting glucose and HbA1c, the impact on results was limited40. Further, the 
120 min follow-up during the OGTT in cohort 2, may have led to nadir glucose being missed in some patients. 
Finally, shortage of extra plasma for re-analysis limited our incretin data to one fasting and one postprandial 
timepoint in Cohort 1 only.
In conclusion, we find that RYGB surgery provides a sustained weight loss 2.5–4 years after RYGB surgery in 
morbidly obese patients with and without preoperative T2D, and that the beneficial effects on glucose metabolism 
seen 1 year after the operation are also present late after surgery in most patients. Maintenance of weight loss and 
improved beta-cell function is important for postoperative glycemic control in patients with preoperative T2D, 
while the increased insulin secretion in response to glucose may explain postprandial hypoglycemia in NGT 
subjects after RYGB.
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